<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Galectin Therapeutics Inc — News on 6ix</title>
<link>https://6ix.com/company/galectin-therapeutics-inc</link>
<description>Latest news and press releases for Galectin Therapeutics Inc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Tue, 31 Mar 2026 04:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/galectin-therapeutics-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835753e78dffbe2df0f6bc8.webp</url>
<title>Galectin Therapeutics Inc</title>
<link>https://6ix.com/company/galectin-therapeutics-inc</link>
</image>
<item>
<title>Galectin Therapeutics Reports 2025 Financial Results and Provides Business Update</title>
<link>https://6ix.com/company/galectin-therapeutics-inc/news/galectin-therapeutics-reports-2025-financial-results-and-provides-business-update</link>
<guid isPermaLink="true">https://6ix.com/company/galectin-therapeutics-inc/news/galectin-therapeutics-reports-2025-financial-results-and-provides-business-update</guid>
<pubDate>Tue, 31 Mar 2026 04:00:00 GMT</pubDate>
<description>NORCROSS, Ga., March 31, 2026 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin</description>
</item>
<item>
<title>Galectin Therapeutics Strengthens Board of Directors with Appointment of Henry Brem, M.D.</title>
<link>https://6ix.com/company/galectin-therapeutics-inc/news/galectin-therapeutics-strengthens-board-of-directors-with-appointment-of-henry-brem-md</link>
<guid isPermaLink="true">https://6ix.com/company/galectin-therapeutics-inc/news/galectin-therapeutics-strengthens-board-of-directors-with-appointment-of-henry-brem-md</guid>
<pubDate>Tue, 17 Mar 2026 04:00:00 GMT</pubDate>
<description>NORCROSS, Ga., March 17, 2026 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of galectin-3-targeted therapeutics for</description>
</item>
<item>
<title>Galectin Therapeutics to Host Virtual KOL Event to Discuss Belapectin Development Program for Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) Cirrhosis and Portal Hypertension, on March 10, 2026 at 12:00 PM ET</title>
<link>https://6ix.com/company/galectin-therapeutics-inc/news/galectin-therapeutics-to-host-virtual-kol-event-to-discuss-belapectin-development-program-for-treatment-of-metabolic-dysfunction-associated-steatohepatitis-mash-cirrhosis-and-portal-hypertension-on-march-10-2026-at-1200-pm-et</link>
<guid isPermaLink="true">https://6ix.com/company/galectin-therapeutics-inc/news/galectin-therapeutics-to-host-virtual-kol-event-to-discuss-belapectin-development-program-for-treatment-of-metabolic-dysfunction-associated-steatohepatitis-mash-cirrhosis-and-portal-hypertension-on-march-10-2026-at-1200-pm-et</guid>
<pubDate>Thu, 26 Feb 2026 21:05:00 GMT</pubDate>
<description>NORCROSS, Ga., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of galectin-3-targeted therapeutics for patients with MASH cirrhosis and portal hypertension, today announced that it will host a virtual key opinion leader (KOL) event on Tuesday, March 10, 2026 at 12:00 PM ET. To register, click here. The event will focus on the unmet need and current treatment landscape for metabolic dysfunction-associated steatohepatitis (MASH) cirrhosis and porta</description>
</item>
<item>
<title>Galectin Therapeutics Provides Regulatory Update Following FDA Written Response and Announces an Additional $10 Million Line of Credit from Richard E. Uihlein Sufficient to Cover Expected Expenditures Through March 2027</title>
<link>https://6ix.com/company/galectin-therapeutics-inc/news/galectin-therapeutics-provides-regulatory-following-130000765</link>
<guid isPermaLink="true">https://6ix.com/company/galectin-therapeutics-inc/news/galectin-therapeutics-provides-regulatory-following-130000765</guid>
<pubDate>Fri, 19 Dec 2025 13:00:00 GMT</pubDate>
<description>NORCROSS, Ga., Dec. 19, 2025 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of galectin-3-targeted therapeutics for patients with MASH cirrhosis and portal hypertension, today announced that the U.S. Food and Drug Administration (FDA) has provided a written response, and subsequent communications, to the Company’s previously submitted Type C meeting request regarding the development program for belapectin, its investigational galectin-3 inhibitor. The FDA con</description>
</item>
<item>
<title>Galectin Therapeutics Reports Financial Results for the quarter ended September 30, 2025, and Provides Business Update</title>
<link>https://6ix.com/company/galectin-therapeutics-inc/news/galectin-therapeutics-reports-financial-results-130000365</link>
<guid isPermaLink="true">https://6ix.com/company/galectin-therapeutics-inc/news/galectin-therapeutics-reports-financial-results-130000365</guid>
<pubDate>Fri, 14 Nov 2025 13:00:00 GMT</pubDate>
<description>NORCROSS, Ga., Nov. 14, 2025 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business update for the three and nine months ended September 30, 2025. “The new NAVIGATE data presented at AASLD further strengthen the clinical and mechanistic profile of belapectin. We continue to see encouraging consistency across key biomarkers—including FibroScan®, ELF, and PRO-C3—al</description>
</item>
<item>
<title>Galectin Therapeutics Presented NAVIGATE Trial Results at the American Association for the Study of Liver Diseases (AASLD) 2025 Annual Meeting</title>
<link>https://6ix.com/company/galectin-therapeutics-inc/news/galectin-therapeutics-presented-navigate-trial-130000252</link>
<guid isPermaLink="true">https://6ix.com/company/galectin-therapeutics-inc/news/galectin-therapeutics-presented-navigate-trial-130000252</guid>
<pubDate>Mon, 10 Nov 2025 13:00:00 GMT</pubDate>
<description>New biomarker analyses from the NAVIGATE trial demonstrated consistent antifibrotic effects of belapectin 2 mg/kgUsing established criteria for clinically meaningful worsening, a lower proportion of patients treated with belapectin 2 mg/kg experienced ≥30% or ≥5 kPa increases in liver stiffness (LSM) by FibroScan® compared with placebo, indicating slowing of fibrosis progression and stabilization of liver functionAcross all ELF fibrosis risk categories, belapectin 2 mg/kg showed a lower incidenc</description>
</item>
<item>
<title>Galectin Therapeutics to Present at the H.C. Wainwright 9th Annual MASH Investor Conference</title>
<link>https://6ix.com/company/galectin-therapeutics-inc/news/galectin-therapeutics-to-present-at-the-hc-wainwright-9th-annual-mash-investor-conference</link>
<guid isPermaLink="true">https://6ix.com/company/galectin-therapeutics-inc/news/galectin-therapeutics-to-present-at-the-hc-wainwright-9th-annual-mash-investor-conference</guid>
<pubDate>Mon, 20 Oct 2025 04:00:00 GMT</pubDate>
<description>NORCROSS, Ga., Oct. 20, 2025 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin</description>
</item>
<item>
<title>Galectin Therapeutics to Present at the American Association for the Study of Liver Disease (AASLD) Liver Meeting 2025</title>
<link>https://6ix.com/company/galectin-therapeutics-inc/news/galectin-therapeutics-present-american-association-120000141</link>
<guid isPermaLink="true">https://6ix.com/company/galectin-therapeutics-inc/news/galectin-therapeutics-present-american-association-120000141</guid>
<pubDate>Tue, 07 Oct 2025 12:00:00 GMT</pubDate>
<description>NORCROSS, Ga., Oct. 07, 2025 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin-3 for patients with MASH cirrhosis and portal hypertension, today announced participation in the AASLD Liver Meeting 2025. The company will deliver two presentations, including one oral and one poster presentation, highlighting data from the NAVIGATE trial assessing belapectin for the treatment of MASH cirrhosis. The meeting will be held November</description>
</item>
<item>
<title>Galectin Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference</title>
<link>https://6ix.com/company/galectin-therapeutics-inc/news/galectin-therapeutics-present-h-c-120000352</link>
<guid isPermaLink="true">https://6ix.com/company/galectin-therapeutics-inc/news/galectin-therapeutics-present-h-c-120000352</guid>
<pubDate>Tue, 02 Sep 2025 12:00:00 GMT</pubDate>
<description>NORCROSS, Ga., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today announced that the company management will participate in the H.C. Wainwright 27th Annual Global Investment Conference, taking place September 8-10, 2025 in New York, NY. H.C. Wainwright 27th Annual Global Investment ConferenceCompany presentation: September 8, 2025, at 1:00 PM ET. Webcast: HEREThe live and archived webcast will</description>
</item>
<item>
<title>Galectin Therapeutics Reports Financial Results for the Quarter Ended June 30, 2025 and Provides Business Update</title>
<link>https://6ix.com/company/galectin-therapeutics-inc/news/galectin-therapeutics-reports-financial-results-120000027</link>
<guid isPermaLink="true">https://6ix.com/company/galectin-therapeutics-inc/news/galectin-therapeutics-reports-financial-results-120000027</guid>
<pubDate>Thu, 14 Aug 2025 12:00:00 GMT</pubDate>
<description>NORCROSS, Ga., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business update for the three and six months ended June 30, 2025. Joel Lewis, Chief Executive Officer and President of Galectin Therapeutics, stated “We are encouraged by the continued analysis of data from our NAVIGATE trial , which further supports the clinical profile of belapectin in p</description>
</item>
<item>
<title>Galectin Therapeutics Announces New $10 Million Credit Line from Richard E. Uihlein, Sufficient to Cover Expected Expenditures Through June 2026</title>
<link>https://6ix.com/company/galectin-therapeutics-inc/news/galectin-therapeutics-announces-10-million-120000822</link>
<guid isPermaLink="true">https://6ix.com/company/galectin-therapeutics-inc/news/galectin-therapeutics-announces-10-million-120000822</guid>
<pubDate>Wed, 09 Jul 2025 12:00:00 GMT</pubDate>
<description>NORCROSS, Ga., July 09, 2025 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of galectin-3-targeted therapeutics for patients with metabolic dysfunction-associated steatohepatitis (MASH) cirrhosis and portal hypertension, announced today it entered into a new $10 million unsecured line of credit facility with Richard E. Uihlein, Chairman of Galectin Board of Directors, and its largest individual stockholder. “Belapectin has the potential to address a significa</description>
</item>
<item>
<title>Galectin Therapeutics to Host Virtual KOL Event to Discuss Belapectin for Treatment of MASH Cirrhosis and Portal Hypertension</title>
<link>https://6ix.com/company/galectin-therapeutics-inc/news/galectin-therapeutics-host-virtual-kol-125600481</link>
<guid isPermaLink="true">https://6ix.com/company/galectin-therapeutics-inc/news/galectin-therapeutics-host-virtual-kol-125600481</guid>
<pubDate>Tue, 10 Jun 2025 12:56:00 GMT</pubDate>
<description>NORCROSS, Ga., June 10, 2025 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin-3 for patients with MASH cirrhosis and portal hypertension, today announced that it will host a virtual key opinion leader (KOL) event on Monday, June 16, 2025 at 12:00 PM ET. To register, click here. The event will focus on the unmet need and current treatment landscape for metabolic dysfunction-associated steatohepatitis (MASH) cirrhosis and port</description>
</item>
<item>
<title>Galectin Therapeutics Reports Financial Results for the Quarter Ended March 31, 2025 and Provides Business Update</title>
<link>https://6ix.com/company/galectin-therapeutics-inc/news/galectin-therapeutics-reports-financial-results-120000767</link>
<guid isPermaLink="true">https://6ix.com/company/galectin-therapeutics-inc/news/galectin-therapeutics-reports-financial-results-120000767</guid>
<pubDate>Thu, 15 May 2025 12:00:00 GMT</pubDate>
<description>NORCROSS, Ga., May 15, 2025 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business update for the three months ended March 31, 2025. Joel Lewis, Chief Executive Officer and President of Galectin Therapeutics, stated “This quarter, we remained laser-focused on advancing additional analyses for belapectin. I was extremely encouraged by the feedback we received last</description>
</item>
<item>
<title>Galectin Therapeutics Presented NAVIGATE Trial Results at the European Association for the Study of the Liver (EASL) 2025 Congress</title>
<link>https://6ix.com/company/galectin-therapeutics-inc/news/galectin-therapeutics-presented-navigate-trial-120000992</link>
<guid isPermaLink="true">https://6ix.com/company/galectin-therapeutics-inc/news/galectin-therapeutics-presented-navigate-trial-120000992</guid>
<pubDate>Mon, 12 May 2025 12:00:00 GMT</pubDate>
<description>Data presentation included efficacy and biomarker analyses from the NAVIGATE trial (n=287). Belapectin 2 mg/kg demonstrated a statistically significant reduction in new varices at 18 months in the per-protocol population (p=0.04). Significantly fewer patients in the belapectin treatment arms experienced worsening of liver stiffness as measured by FibroScan®, reinforcing the potential beneficial effect of belapectin in halting the progression of MASH cirrhosis. NORCROSS, Ga., May 12, 2025 (GLOBE</description>
</item>
<item>
<title>Galectin Therapeutics to Present at the European Association for the Study of the Liver (EASL) 2025 Congress</title>
<link>https://6ix.com/company/galectin-therapeutics-inc/news/galectin-therapeutics-present-european-association-120000228</link>
<guid isPermaLink="true">https://6ix.com/company/galectin-therapeutics-inc/news/galectin-therapeutics-present-european-association-120000228</guid>
<pubDate>Tue, 15 Apr 2025 12:00:00 GMT</pubDate>
<description>NORCROSS, Ga., April 15, 2025 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin-3 for patients with MASH cirrhosis and portal hypertension, today announced that it will attend the EASL 2025 meeting and deliver a scientific presentation in the late-breaking oral presentation session. The meeting will be held May 7-10, 2025, in Amsterdam, Netherlands. “We are excited that data from our NAVIGATE study, evaluating belapectin, a g</description>
</item>
<item>
<title>Galectin Therapeutics Reports 2024 Financial Results and Provides Business Update</title>
<link>https://6ix.com/company/galectin-therapeutics-inc/news/galectin-therapeutics-reports-2024-financial-120000355</link>
<guid isPermaLink="true">https://6ix.com/company/galectin-therapeutics-inc/news/galectin-therapeutics-reports-2024-financial-120000355</guid>
<pubDate>Mon, 31 Mar 2025 12:00:00 GMT</pubDate>
<description>NORCROSS, Ga., March 31, 2025 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business update for the year ended December 31, 2024. Joel Lewis, Chief Executive Officer and President of Galectin Therapeutics, said “In the U.S. approximately 5 million adults are affected by MASH cirrhosis and clinically significant portal hypertension. The need for new treatments tha</description>
</item>
<item>
<title>Galectin Therapeutics Reports Significant Reduction in New Varices with Belapectin in U.S. Patient Population from the NAVIGATE Trial</title>
<link>https://6ix.com/company/galectin-therapeutics-inc/news/galectin-therapeutics-reports-significant-reduction-130000059</link>
<guid isPermaLink="true">https://6ix.com/company/galectin-therapeutics-inc/news/galectin-therapeutics-reports-significant-reduction-130000059</guid>
<pubDate>Tue, 18 Feb 2025 13:00:00 GMT</pubDate>
<description>Additional analysis of data from the NAVIGATE trial showed statistically significant 68.1% (p=0.02) reduction in the incidence of new varices with belapectin vs placebo in per-protocol patients (completers) enrolled in the U.S.New estimates indicate around 3 million adults in the U.S. suffer from MASH cirrhosis and clinically significant portal hypertension1, for which there are no FDA approved therapiesFull analysis of the NAVIGATE trial is ongoing; additional data, including from patients comp</description>
</item>
<item>
<title>Galectin Therapeutics to Present at the 2025 MASH-TAG Conference</title>
<link>https://6ix.com/company/galectin-therapeutics-inc/news/galectin-therapeutics-to-present-at-the-2025-mash-tag-conference</link>
<guid isPermaLink="true">https://6ix.com/company/galectin-therapeutics-inc/news/galectin-therapeutics-to-present-at-the-2025-mash-tag-conference</guid>
<pubDate>Fri, 10 Jan 2025 05:00:00 GMT</pubDate>
<description>NORCROSS, Ga., Jan. 10, 2025 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin</description>
</item>
<item>
<title>Galectin Therapeutics Announces Top-Line Results of NAVIGATE Clinical Trial Evaluating Belapectin in Patients with Cirrhotic Portal Hypertension Caused by MASH</title>
<link>https://6ix.com/company/galectin-therapeutics-inc/news/galectin-therapeutics-announces-top-line-results-of-navigate-clinical-trial-evaluating-belapectin-in-patients-with-cirrhotic-portal-hypertension-caused-by-mash</link>
<guid isPermaLink="true">https://6ix.com/company/galectin-therapeutics-inc/news/galectin-therapeutics-announces-top-line-results-of-navigate-clinical-trial-evaluating-belapectin-in-patients-with-cirrhotic-portal-hypertension-caused-by-mash</guid>
<pubDate>Fri, 20 Dec 2024 05:00:00 GMT</pubDate>
<description>In the pre-specified per-protocol population, belapectin showed a statistically significant reduction (p-value While there was a favorable trend for incidence</description>
</item>
<item>
<title>Galectin Therapeutics Presents Three Abstracts at the American Association for the Study of Liver Diseases (AASLD) 2024 Liver Meeting</title>
<link>https://6ix.com/company/galectin-therapeutics-inc/news/galectin-therapeutics-presents-three-abstracts-at-the-american-association-for-the-study-of-liver-diseases-aasld-2024-liver-meeting</link>
<guid isPermaLink="true">https://6ix.com/company/galectin-therapeutics-inc/news/galectin-therapeutics-presents-three-abstracts-at-the-american-association-for-the-study-of-liver-diseases-aasld-2024-liver-meeting</guid>
<pubDate>Mon, 18 Nov 2024 05:00:00 GMT</pubDate>
<description>Patient population for the NAVIGATE trial is based on non-invasive tests and clinical criteria utilizing latest treatment guidelines for portal hypertension</description>
</item>
</channel>
</rss>